| Literature DB >> 23791548 |
C A Batten1, L Edwards, C A L Oura.
Abstract
One of the big surprises about the devastating outbreak of bluetongue serotype-8 that spread across Northern and Western Europe between 2006 and 2008 was how relatively quickly the virus was controlled and eradicated from affected countries. This was at least in part attributed to the high levels of vaccine coverage achieved in affected countries. A previous study revealed that neutralising antibodies persisted in the majority of vaccinated cattle for at least 3 years post-vaccination, indicating that cattle are likely to be protected for this time period. The current study revealed that neutralising antibodies persisted in the same group of cattle for up to 4 years post-vaccination, and that neutralising antibodies persisted for up to 2.5 years in sheep that had been vaccinated on two occasions one year apart. These results have implications for future bluetongue surveillance programmes and vaccine control strategies.Entities:
Keywords: Bluetongue; Humoral response; Inactivated vaccines; Protection
Mesh:
Substances:
Year: 2013 PMID: 23791548 PMCID: PMC3763366 DOI: 10.1016/j.vaccine.2013.06.033
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641
Persistence of antibodies, measured by ELISA and SNT, in the milk and blood of adult dairy cattle four years post-vaccination with a BTV-8 inactivated vaccine.
| Cow number | Milk ELISA (%S/P) | Early detection ELISA (%S/P) | SNT log10 | |||
|---|---|---|---|---|---|---|
| 2011 | 2012 | 2011 | 2012 | 2011 | 2012 | |
| 1 | Pos (290) | Pos (153) | Pos (184) | Pos (254) | Pos (1.18) | Pos (1.48) |
| 2 | Pos (221) | Pos (184) | Pos (251) | Pos (1.48) | Pos (1.00) | |
| 3 | Pos (262) | Pos (142) | Pos (165) | Pos (267) | Pos (1.78) | Pos (1.78) |
| 4 | Pos (178) | Pos (224) | Pos (1.60) | Pos (1.48) | ||
| 5 | Pos (307) | No sample | Pos (193) | Pos (280) | Pos (1.00) | Pos (1.78) |
| 6 | Pos (305) | Pos (144) | Pos (190) | Pos (255) | Pos (2.38) | Pos (2.20) |
| 7 | Pos (206) | Pos (134) | Pos (193) | Pos (267) | Pos (1.60) | Pos (2.20) |
| 8 | Pos (140) | Pos (113) | Pos (193) | Pos (280) | Pos (2.20) | Pos (1.78) |
| 9 | Pos (301) | Pos (145) | Pos (183) | Pos (262) | Pos (1.78) | Pos (1.78) |
| 10 | Pos (295) | Pos (146) | Pos (192) | Pos (255) | Pos (2.08) | Pos (2.38) |
| 11 | Pos (292) | Pos (146) | Pos (122) | Pos (185) | Pos (1.60) | Pos (1.90) |
| 12 | Pos (189) | Pos (125) | Pos (153) | Pos (230) | Pos (1.18) | Pos (1.60) |
| 13 | Pos (281) | Pos (131) | Pos (193) | Pos (280) | Pos (1.48) | Pos (1.18) |
| 14 | Pos (286) | Pos (139) | Pos (170) | Pos (240) | Pos (1.18) | Pos (1.60) |
| 15 | Pos (229) | Pos (125) | Pos (183) | Pos (264) | Pos (1.18) | Pos (1.00) |
| 16 | Pos (298) | Pos (152) | Pos (187) | Pos (266) | Pos (1.78) | Pos (2.08) |
| 17 | Pos (304) | Pos (148) | Pos (193) | Pos (266) | Pos (1.30) | Pos (1.78) |
| 18 | Pos (300) | Pos (137) | Pos (185) | Pos (268) | Pos (2.51) | Pos (1.90) |
| 19 | Inc (98) | Pos (165) | Pos (198) | Pos (1.00) | Pos (1.18) | |
| 20 | Pos (241) | Pos (141) | Pos (193) | Pos (276) | Pos (1.30) | Pos (1.48) |
| 21 | Pos (247) | Pos (124) | Pos (191) | Pos (262) | Pos (1.48) | Pos (1.18) |
| 22 | Pos (260) | Pos (114) | Pos (193) | Pos (240) | Pos (1.60) | Pos (1.60) |
| 23 | Pos (306) | Pos (150) | Pos (193) | Pos (270) | Pos (1.78) | Pos (1.78) |
| 24 | Pos (306) | Pos (153) | Pos (189) | Pos (268) | Pos (1.00) | Pos (1.18) |
| 25 | Pos (301) | Pos (151) | Pos (187) | Pos (269) | Pos (1.48) | Pos (1.60) |
| 26 | ||||||
| 27 | Pos (135) | Pos (176) | Pos (263) | Pos (1.18) | Pos (1.18) | |
| 28 | Pos (107) | Pos (99) | Pos (1.30) | Pos (1.78) | ||
| 29 | Pos (268) | Pos (137) | Pos (181) | Pos (248) | Pos (1.60) | Pos (1.60) |
SNT: serum neutralisation test; Pos: positive; Neg: negative; Inc: inconclusive.
% S/P: percentage of positivity compared to the positive control.
Bold value shows the negative results.
Individual samples: negative ≤90%, inconclusive 90–110%, positive ≥110%.
Negative ≤25%, inconclusive 25–30%, positive ≥30%.
Persistence of antibodies, measured by ELISA and SNT, in the blood of sheep 2.5 years post-vaccination (2 vaccines given one year apart) with a BTV-8 inactivated vaccine.
| Animal number | Early detection ELISA (%S/P) | SNT log10 |
|---|---|---|
| 1 | Pos (242) | Pos (1.90) |
| 2 | Pos (256) | Pos (1.78) |
| 3 | Pos (231) | Pos (1.48) |
| 4 | Pos (256) | Pos (1.90) |
| 5 | Pos (231) | Pos (1.48) |
| 6 | Pos (249) | Pos (2.20) |
| 7 | Pos (261) | Pos (1.60) |
| 8 | Pos (241) | Pos (2.08) |
| 9 | Pos (242) | Pos (2.08) |
| 10 | Pos (244) | Pos (1.60) |
| 11 | Pos (181) | Pos (1.78) |
| 12 | Pos (253) | Pos (1.90) |
| 13 | Pos (194) | Pos (2.08) |
| 14 | Pos (251) | Pos (1.30) |
| 15 | Pos (239) | Pos (1.60) |
| 16 | Pos (247) | Pos (1.60) |
| 17 | Pos (252) | Pos (2.38) |
| 18 | Pos (254) | Pos (2.20) |
| 19 | Pos (229) | Pos (1.60) |
| 20 | Pos (268) | Pos (2.08) |
| 21 | Pos (232) | Pos (2.08) |
| 22 | Pos (216) | Pos (2.38) |
| 23 | Pos (231) | Pos (1.78) |
SNT: serum neutralisation test; Pos: positive; Neg: negative; Inc: inconclusive.
% S/P: percentage of positivity compared to the positive control.
Negative ≤25%, inconclusive 25–30%, positive ≥30%.